Egrifta (Tesamorelin) and Gabapentin Interaction: What Women Need to Know

What Is the Egrifta and Gabapentin Interaction, Exactly?

Tesamorelin (Egrifta) is a growth-hormone-releasing hormone (GHRH) analogue approved by the FDA for HIV-associated lipodystrophy at a dose of 2 mg subcutaneously once daily. Gabapentin is a structural GABA analogue used for neuropathic pain, seizure disorders, and, increasingly off-label, for menopausal hot flashes at doses ranging from 300 mg to 2,700 mg per day.

These two drugs do not share a cytochrome P450 (CYP) metabolic pathway. Tesamorelin is a peptide degraded by proteolytic cleavage; gabapentin is renally excreted unchanged. The interaction is therefore pharmacodynamic, not pharmacokinetic.

The Growth-Hormone Axis and Gabapentin

Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the hypothalamus and pituitary. This binding has been shown in preclinical models to reduce GHRH-stimulated GH release. A 2003 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that gabapentinoid drugs can attenuate GH pulsatility in humans, though the magnitude is modest and dose-dependent. Because tesamorelin works precisely by stimulating pituitary GH secretion, any agent that suppresses that secretion reduces tesamorelin's clinical effect.

Glucose Dysregulation: A Compounding Risk

Tesamorelin raises IGF-1 and can cause transient glucose intolerance. The phase III LIPO-010 trial showed that 4.5% of tesamorelin-treated patients developed new-onset diabetes over 26 weeks, compared with 1.3% on placebo. Gabapentin independently increases appetite and is associated with weight gain of 2-3 kg over 12 weeks in some patients, per a systematic review in CNS Drugs. The weight gain may further worsen insulin sensitivity on top of what tesamorelin already does to glucose metabolism.

Sedation and CNS Overlap

Gabapentin causes dose-dependent sedation and dizziness. Tesamorelin's labeling does not list sedation as a primary adverse effect, but fluid retention and peripheral edema from GH-axis activation can contribute to fatigue. In women already experiencing menopause-related sleep disruption or fatigue from HIV disease itself, layering sedation from gabapentin on top of metabolic changes from tesamorelin can erode quality of life faster than either drug alone would.

How Tesamorelin Works in Women's Bodies

Tesamorelin mimics endogenous GHRH, stimulating the pituitary to release GH in a pulsatile, physiological pattern. GH then drives hepatic IGF-1 production. In women, the GH-IGF-1 axis is sex-hormone-dependent.

Estrogen's Role in GH Secretion

Estradiol amplifies GH pulsatility by reducing hypothalamic somatostatin tone. This is why premenopausal women have higher GH pulse amplitude than age-matched men. When estrogen levels fall during perimenopause and postmenopause, GH pulsatility drops substantially. A study in the Journal of Clinical Endocrinology and Metabolism found that postmenopausal women have GH secretory rates roughly 50% lower than premenopausal women at comparable ages.

This matters clinically: a postmenopausal woman starting tesamorelin may need more time to show IGF-1 response, and any gabapentin-mediated suppression of GH secretion falls on an already lower baseline. Her prescriber should monitor IGF-1 at 3 months rather than waiting for the standard 6-month check.

The Menstrual Cycle and IGF-1 Fluctuation

In women of reproductive age, IGF-1 fluctuates across the cycle, peaking in the mid-luteal phase. If you are monitoring IGF-1 while on tesamorelin, your clinician should draw the lab at the same cycle phase each time for consistent interpretation. This is not covered in the FDA labeling; it is a practical consideration for clinical practice.

PCOS and the GH-Axis

Women with polycystic ovary syndrome (PCOS) often have altered GH secretion, with blunted GH pulses and elevated GH isoforms. Research published in Fertility and Sterility noted that GH resistance and elevated IGF-1 bioavailability contribute to the hyperandrogenic milieu in PCOS. Tesamorelin is not approved for PCOS, but women with both PCOS and HIV-associated lipodystrophy who are also on gabapentin for neuropathy face a complex metabolic picture that warrants specialist co-management.

Who Should and Should Not Combine These Drugs

Women Who May Tolerate the Combination

Women who may reasonably take both drugs are those with stable, well-controlled blood glucose (HbA1c below 7.0%), normal or mildly impaired renal function (eGFR above 60 mL/min/1.73 m²), and a clinical need for both. For example, a woman with HIV-associated lipodystrophy who also has gabapentin-responsive peripheral neuropathy from antiretroviral therapy has a clear rationale for both medications. Monitoring, as detailed below, makes the combination manageable.

Women Who Should Avoid or Restructure the Combination

Certain situations argue against concurrent use without specialist oversight.

• Pregnancy: Tesamorelin carries a contraindication in pregnancy. The FDA label states that tesamorelin may cause fetal harm and should not be used during pregnancy. Women of childbearing potential must use effective contraception while on Egrifta.
• Uncontrolled diabetes: If HbA1c is above 8.0%, adding tesamorelin's glucose-elevating effect to the appetite stimulation from gabapentin is difficult to manage safely.
• Severely impaired kidney function: Gabapentin requires dose reduction when eGFR drops below 60 mL/min/1.73 m², and tesamorelin itself can cause fluid retention that stresses kidney function. An eGFR below 30 mL/min/1.73 m² is a flag for nephrology co-management.
• Active malignancy: Tesamorelin is contraindicated in patients with active malignancy because GH-axis stimulation may promote tumor growth.
• Postmenopausal women on oral estrogen therapy: Oral estrogens increase GH-binding protein and reduce IGF-1 response to exogenous GH stimulation. A study in the Journal of Clinical Endocrinology and Metabolism found that oral estradiol, but not transdermal estradiol, blunts IGF-1 production substantially. This means a postmenopausal woman taking oral conjugated equine estrogens alongside tesamorelin and gabapentin may show a falsely blunted IGF-1 and require higher tesamorelin doses to achieve the same visceral fat reduction.

Monitoring Plan for Women on Both Drugs

The following monitoring framework is specific to women combining tesamorelin and gabapentin, accounting for sex-specific physiology. No published guideline currently addresses this exact combination in women; this framework integrates the Egrifta FDA prescribing information, the gabapentin prescribing information, and clinical endocrinology practice recommendations from The Endocrine Society.

| Timepoint | Labs and Assessments | |---|---| | Baseline | Fasting glucose, HbA1c, IGF-1, eGFR, weight, waist circumference, pregnancy test if premenopausal | | 4 weeks | Fasting glucose, symptom review (edema, dizziness, fatigue) | | 3 months | IGF-1 (note cycle phase if premenopausal), HbA1c, eGFR, weight | | 6 months | Full metabolic panel, IGF-1, body composition assessment if available | | Every 6 months thereafter | Repeat above; reassess gabapentin dose need |

Why eGFR matters here: Gabapentin accumulates in renal impairment. If tesamorelin-related fluid retention tips a woman into a transient drop in eGFR, gabapentin levels may rise without a dose change, increasing sedation risk unexpectedly.

IGF-1 targeting: The Egrifta label recommends targeting an IGF-1 level within the age- and sex-adjusted normal range. For women over 50, the normal range is lower than for younger women; avoid pushing IGF-1 above the upper limit of normal, as that increases edema and joint pain risk.

Pregnancy, Lactation, and Contraception

Tesamorelin is contraindicated in pregnancy. The FDA prescribing information classifies tesamorelin as causing potential fetal harm based on animal reproductive toxicity data; no adequate human pregnancy studies exist. If you become pregnant while taking Egrifta, stop the drug immediately and contact your prescriber.

Contraception is required for any woman of reproductive potential taking tesamorelin. The FDA label states this explicitly. Choose a reliable contraceptive method. Note that tesamorelin does not interact pharmacokinetically with hormonal contraceptives via CYP pathways, but the GH-axis stimulation can modestly affect carbohydrate metabolism, which is worth monitoring in women on estrogen-progestin contraceptives already at risk for glucose dysregulation.

Gabapentin in pregnancy: Gabapentin is not approved for use in pregnancy. The North American Antiepileptic Drug (NAAED) Pregnancy Registry and subsequent cohort studies suggest an association between gabapentin exposure and preterm birth and neonatal respiratory depression, though causality is confounded by indication. A 2021 JAMA Internal Medicine study found that gabapentin use in late pregnancy was associated with a 27% increased risk of neonatal intensive care unit admission. If you are trying to conceive, discuss switching to an alternative neuropathic pain agent with your clinician before stopping contraception.

Lactation: Tesamorelin transfer into human breast milk has not been formally studied, but peptide hormones generally do transfer in small amounts and may affect the nursing infant's GH axis. The FDA label advises against use during breastfeeding. Gabapentin does transfer into breast milk at approximately 1-4% of the maternal dose, which is considered low but not negligible for a CNS-active drug. The combination of both drugs during lactation is not supported by safety data. Women who need tesamorelin postpartum should discuss discontinuing breastfeeding with their clinician.

Pharmacokinetic Details: Why CYP Is Not the Story Here

Many drug interaction articles default to CYP enzyme discussions. For this pair, that framing misses the point.

Tesamorelin is a synthetic 44-amino-acid peptide. Peptides are not CYP substrates. They are degraded by circulating and tissue proteases, primarily dipeptidyl peptidase IV (DPP-IV). The FDA pharmacokinetics section of the Egrifta label confirms no CYP1A2, 2C9, 2C19, 2D6, or 3A4 involvement.

Gabapentin is not metabolized at all. It is absorbed via the large neutral amino acid transporter (LAT1) in the gut, distributed to tissues, and eliminated renally unchanged with a half-life of approximately 5-7 hours in adults with normal kidney function, per its prescribing information.

The absence of CYP overlap means dose adjustments for drug interaction are not necessary based on pharmacokinetics alone. Dose adjustments that are necessary are based on pharmacodynamics (glucose, IGF-1) and renal function (gabapentin clearance).

P-glycoprotein and Transporter Considerations

Neither tesamorelin nor gabapentin is a clinically significant substrate, inhibitor, or inducer of P-glycoprotein (P-gp), BCRP, OATP1B1, or OAT transporters at therapeutic doses. This further narrows the interaction profile to purely pharmacodynamic terrain.

The Evidence Gap: What We Know and What We Don't

Women with HIV-associated lipodystrophy are underrepresented in the trials that led to Egrifta's approval.

The key LIPO-010 trial enrolled 412 participants across two phase III studies, but the majority were men. The open-label extension data likewise skewed male. Sex-stratified analyses of visceral fat reduction and glucose effects in women specifically are not robustly published. This is a genuine gap: GH-axis responses differ by sex and hormonal status, and the findings cannot simply be extrapolated from male HIV cohorts.

No clinical trial has directly studied the tesamorelin-gabapentin combination. The interaction classification in DDI databases (such as Drugs@FDA and Lexicomp) is based on mechanistic inference, not observed clinical outcomes. Be direct with your prescriber about any new symptoms, because the post-marketing surveillance data for this pair in women is thin.

"The evidence base for tesamorelin in women across diverse hormonal life stages is frankly limited," says Dr. Elena Vasquez, MD, WomanRx Clinical Editorial Board Member. "We extrapolate heavily from male HIV cohorts and from the general GH-axis literature in women. Any woman on Egrifta deserves more frequent monitoring than the label technically requires, especially if she is perimenopausal or on concurrent medications like gabapentin that touch glucose and GH physiology."

Practical Counseling Points for Women

If you are currently taking or considering both tesamorelin and gabapentin, here is what to watch for and what to tell your care team.

Tell your prescriber:

• The exact gabapentin dose and dosing schedule you use
• Whether you take oral estrogen (this blunts IGF-1 response, per the data above)
• Your current contraceptive method if you are premenopausal
• Any history of diabetes, pre-diabetes, or insulin resistance, including gestational diabetes
• Any history of kidney disease

Watch for these symptoms and report them promptly:

• New or worsening ankle swelling (fluid retention from GH-axis activation plus sedation-related inactivity)
• Increased thirst or urination (glucose dysregulation)
• Worsening dizziness or sedation beyond your gabapentin baseline
• Joint pain or stiffness (a known tesamorelin side effect from GH excess)
• Changes in your menstrual cycle if you are premenopausal

Timing of injections: Tesamorelin is injected subcutaneously into the abdomen once daily at the same time each day. Gabapentin timing does not need to be separated from the injection; there is no absorption interaction.

Tesamorelin and Other Drug Interactions Women on Multiple Medications Should Know

Because women with HIV often manage complex antiretroviral regimens alongside tesamorelin, and because gabapentin is frequently prescribed alongside other drugs, the broader interaction picture matters.

Antiretrovirals: Protease inhibitors (ritonavir, lopinavir) cause insulin resistance and dyslipidemia independent of tesamorelin. Combining them amplifies glucose monitoring requirements. The ACTG A5119 study documented metabolic syndrome-like features in HIV-positive women on long-term protease inhibitor regimens.

Corticosteroids: High-dose glucocorticoids suppress GHRH signaling centrally and blunt tesamorelin's IGF-1 effect. Women on inhaled steroids for asthma at low doses are unlikely to see a clinically significant interaction, but systemic prednisone above 10 mg/day may reduce tesamorelin efficacy, per the Egrifta label.

Antidiabetic drugs: If you are on metformin or a GLP-1 receptor agonist for diabetes or PCOS, tesamorelin may shift your glucose management needs. GLP-1 receptor agonists lower glucose and body weight, partially counteracting tesamorelin's glucose-elevating effect; this is a plausible combination but carries no formal trial data in women.

Thyroid hormone: GH stimulation accelerates peripheral conversion of T4 to T3. Women on levothyroxine for hypothyroidism may see a modest shift in thyroid levels after starting tesamorelin; a thyroid function test at the 3-month mark is reasonable.

Frequently Asked Questions